Both Immunization with Protein and Recombinant Vaccinia Virus Can Stimulate CTL Specific for the E7 Protein of Human Papilloma Virus 16 in H‐2d Mice

Scandinavian Journal of Immunology

Volumn 42, Issue 5, 1995, Pages 557-563

  ZHU, X ^a   TOMMASINO, M ^c   VOUSDEN, K ^d   SADOVNIKAVA, E ^b   RAPPUOLI, R ^e   CRAWFORD, L ^c   KAST, M ^f   MELIEF, C J M ^f   BEVERLEY, P C L ^b   STAUSS, H J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^e IRIS   (France)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; RECOMBINANT PROTEIN; VACCINE; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CYTOTOXIC T LYMPHOCYTE; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS RECOMBINANT; WART VIRUS;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMAL; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES;

EID: 0028849989     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.1995.tb03696.x     Document Type: Article

References (28)

1. Prospects of cervical cancer vaccines
2. Correlation of modified human papilloma virus early gene expression with altered growth properties in C4‐1 cervical carcinoma cells
3. Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells
4. Human papillomavirus type 16 immortalized cervical keratinocytes contain transcripts encoding E6, E7, and E2 initiated at the P97 promoter and express high levels of E7
5. Development of malignancy following renal transplantation in Australia and New Zealand
6. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7
7. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen
8. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA‐4
9. Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
10. Limitations of Predictive Motifs Revealed by CTL Epitope Mapping of the Human Papilloma Virus E7 Protein
11. Vaccinia virus: a tool for research and vaccine development
12. Heterologous protection against influenza by injection of DNA encoding a viral protein [see comments]
13. The biochemistry and cell biology of antigen processing and presentation
14. Cytotoxic T lymphocytes against soluble protein
15. Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I‐ and class II‐restricted cytotoxic T cell recognition
16. Selection of highly transferable variant from mouse mastocytoma P815
17. Identification of two cytotoxic T lymphocyte‐recognised epitopes in the Ras protein
18. Advanced adjuvant formulations for use with recombinant subunit vaccines
19. Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T‐cell epitopes in human papilloma virus
20. HPV16 E7 phosphorylation in fission yeast: characterization and biological effects
21. Systemic cytokine profiles in BALB/C mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants
22. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu‐3/T4 molecule
23. Therapy with monoclonal antibodies by elimination of T‐cell subsets in vivo
24. Immune response to human papilloma virus type 16 E6 gene in live vaccinia vector
25. Immune responses to HPV 16 E7
26. Phogocytic processing of exogenous particulate antigens by macrophages for presentation by MHC class I molecules
27. Identification of a human melanoma antigen recognized by tumopur infiltrating lymphocytes associated with in vivo tumor rejection
28. Clinical and immunologic responses to human immunodeficiency virus type 1SF2 gp 120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non‐HIV‐infected human volunteers